Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates
- 28 October 2005
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 15 (11) , 1565-1585
- https://doi.org/10.1517/13543776.15.11.1565
Abstract
The androgen receptor (AR) is a nuclear hormone receptor that, upon binding to testosterone, dihydrotestosterone (DHT) and other endogenous androgens, supports the development, growth and maintenance of masculine features through activation of anabolic and androgenic metabolism. The AR has been demonstrated to be a productive therapeutic target. AR ligands in clinical practice include androgenic steroids, antiandrogenic steroids and antiandrogenic nonsteroidals. Of primary importance for this review are nonsteroidal selective AR modulators (SARMs) that have tissue-specific agonist and/or antagonist activities. The AR has a myriad of peripheral and central functions that can be modulated in a pleiotropic and tissue-specific fashion using the increasingly diverse collection of SARMs discussed herein. This suggests that SARMs will have a high level of clinical utility for a wide variety of health conditions. The patent literature focusing on SARMs is reviewed and reveals multiple chemical classes in various stages of preclinical and clinical development. Emphasis is placed on selected disease states for which SARMs show potential for therapeutic use in clinical practice.Keywords
This publication has 54 references indexed in Scilit:
- Synthesis of irreversibly binding bicalutamide analogs for imaging studiesTetrahedron Letters, 2005
- Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences, 2005
- Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleusBioorganic & Medicinal Chemistry Letters, 2004
- Musculoskeletal agingCurrent Opinion in Rheumatology, 2004
- Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2003
- New Modalities of Transdermal Testosterone ReplacementTreatments in Endocrinology, 2003
- Testosterone supplementation: what and how to giveThe Aging Male, 2003
- Androgen responsiveness of the pituitary gonadotrope cell line LbetaT2Journal of Endocrinology, 2001
- Discovery of Nonsteroidal AndrogensBiochemical and Biophysical Research Communications, 1998
- The aromatization of androstenedione by human adipose and liver tissueThe Journal of Steroid Biochemistry and Molecular Biology, 1980